Overview

Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

Status:
Active, not recruiting

Trial end date:
2038-01-01

Target enrollment:

Participant gender:

Summary

The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.

Phase:

Phase 1

Details

Lead Sponsor:

Kite, A Gilead Company

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate